Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE-MI
2023-509268-26-00Phase 4Authorised
- Sponsor
- Amgen
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 4, randomised trial in myocardial infarction (MI) and dyslipidemia comparing Very early evolocumab plus standard of care with Standard of care alone (2 arms). Primary endpoint: Total (first and subsequent) composite of myocardial infarction, ischemic stroke, any arterial revascularization procedure, and all-cause death. Planned start Apr 2024; status: authorised.
02
Drugs
evolocumab
03
Conditions
myocardial infarction (MI)dyslipidemia
Beyond the preview
Go deeper on 2023-509268-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509268-26-00.